This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on blood glucose control in insulin naive type 2 diabetes failing on secondary oral hypoglycaemic agent (OHA).

Inclusion Criteria:

• Type 2 diabetes
• Insulin naive diabetes
• Current treatment with OHA, secondary failure
• Body mass index (BMI) below 40 kg/m2
• HbA1c over 8.5%
• Willing and able to start with insulin therapy and to perform self-blood glucose monitoring

Exclusion Criteria:

• History of drug or alcohol abuse
• Receipt of the investigational drug within the last month prior to this trial
• Known or suspected allergy to trial products or related products
• Severe uncontrolled hypertension
• Any disease or condition, which the Investigator feels, would interfere with the trial